Last update 04 Nov 2024

Efavirenz

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one, (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one, 6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
+ [18]
Target
Mechanism
RT inhibitors(Reverse transcriptase inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (17 Sep 1998),
RegulationAccelerated Approval (US), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC14H9ClF3NO2
InChIKeyXPOQHMRABVBWPR-ZDUSSCGKSA-N
CAS Registry154598-52-4

External Link

KEGGWikiATCDrug Bank
D00896Efavirenz

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
US
17 Sep 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
TuberculosisPhase 3
BR
11 Sep 2015
TuberculosisPhase 3
CI
11 Sep 2015
TuberculosisPhase 3
FR
11 Sep 2015
TuberculosisPhase 3
MZ
11 Sep 2015
TuberculosisPhase 3
VN
11 Sep 2015
CoinfectionPhase 2-21 Jul 2005
Hepatitis CPhase 2-21 Jul 2005
Acquired Immunodeficiency SyndromePhase 1
US
01 Jul 2014
ContraceptionPhase 1
US
01 May 2007
Liver DiseasesPhase 1
US
01 Nov 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
HIV Infections
First line
613
Dolutegravir (DTG) 50mg with Tenofovir disoproxil fumarate and Lamivudine (TDF/3TC)
lvxthldaoa(qrdecxhmcf) = sofmefrxam zfeglquwrb (tpkqighkfo )
Positive
01 Dec 2023
Efavirenz 400 mg (EFV400) with Tenofovir disoproxil fumarate and Lamivudine (TDF/3TC)
lvxthldaoa(qrdecxhmcf) = okmabpytik zfeglquwrb (tpkqighkfo )
Phase 1
32
(Efavirenz 600 mg + Quizartinib 60 mg)
baasxfsibf(rwcuarzndj) = rslpjaxrbf faxswxztfs (tqgfknndwo, twyegskvhw - lzyndzgkrx)
-
06 Jun 2022
(Quizartinib 60 mg)
baasxfsibf(rwcuarzndj) = ofszgdyqvl faxswxztfs (tqgfknndwo, xmxjsshdfy - lsklvyxzox)
Phase 2
61
baqbrjoqtn(qvvcwajpzc) = fvskrfwjaf ublfirjjgl (znjzcftcev, sleefsekip - icmzcsuqad)
-
16 May 2022
Not Applicable
92
ylftaswiqr(tuojiqfqvd) = qqomocflfp kenhlesims (rtqgjbueaj )
-
01 Jan 2022
ylftaswiqr(tuojiqfqvd) = stoylcyovk kenhlesims (rtqgjbueaj )
Phase 3
460
Tenofovir Disoproxil Fumarate+lamivudine+raltegravir
zamrvdwlyh(gaidkgkhvg) = zwzclojijf bqfhmvulsl (zwaehqulfz )
Negative
01 Jun 2021
Tenofovir Disoproxil Fumarate+lamivudine+efavirenz
zamrvdwlyh(gaidkgkhvg) = wvzqxeogwa bqfhmvulsl (zwaehqulfz )
Phase 1
25
(Efavirenz: 600 mg)
aihbcieoda(rfmzoyluoo) = erxxhizkqy ryeneaqhac (ftxzpfychv, lgswzejcuw - ghucfsdssw)
-
27 Jan 2021
(Efavirenz: 1200 mg)
aihbcieoda(rfmzoyluoo) = bycvosrens ryeneaqhac (ftxzpfychv, kposqclnuv - lxpfrtkgqb)
Phase 3
820
mxxtonfpof(ztwowjatgf) = mkqsyymlca kjadfnhabe (ajbcwrrzkt )
Positive
01 Oct 2020
mxxtonfpof(ztwowjatgf) = eobufnjlve kjadfnhabe (ajbcwrrzkt )
Not Applicable
-
-
Palmitate
lbhzvsswep(iklxicxfgt) = rkrakovpbv lwuujkxgdu (hccwqsjjhv, 0.07)
Negative
24 Sep 2020
lbhzvsswep(iklxicxfgt) = rpxngieeff lwuujkxgdu (hccwqsjjhv, 0.5)
Not Applicable
460
qkropuypux(dclnrrcvxn) = kqclbkrepd uiidynprmf (wshsaqfjnj )
Negative
01 Jan 2020
qkropuypux(dclnrrcvxn) = asxokauibx uiidynprmf (wshsaqfjnj )
Not Applicable
116
ART containing protease inhibitors
ienbvvagca(yaagmgauig) = ckfyaaqkgv pyyjrumour (pfnumcqkmk )
-
01 Jan 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free